Hydroxyurea belongs to the antineoplastic/antimetabolite therapeutic class, primarily used to control cell proliferation in myeloproliferative disorders.

Complete Blood Counts (CBC) are typically monitored weekly or bi-weekly during early initiation to closely track bone marrow suppression.

Yes, it increases the synthesis of fetal hemoglobin (HbF), which prevents the sickling of red blood cells and reduces vaso-occlusive painful crises.

As a cytotoxic drug, handlers should wear gloves or wash hands thoroughly immediately after touching the capsules to avoid accidental absorption.

Inform your physician immediately. Hydroxyurea-induced cutaneous vasculitic ulcers may require a reduction in dosage or discontinuation of therapy.

Live vaccines should be avoided due to the patient's compromised immune status caused by drug-induced myelosuppression.

Yes, it is highly teratogenic and genotoxic. Strict contraception is mandatory for both male and female patients during and after treatment.

Severe fever, chills, unusual bleeding or bruising, deep mouth sores, and unexplained shortness of breath.

It can be taken with or without food. Drink a full glass of water with each dose to facilitate normal systemic clearance.

It is rapidly absorbed and cleared via renal mechanisms, with its blood-clearing half-life lasting approximately 2 to 4 hours.